CVS Health Co. (NYSE:CVS) Shares Bought by NBT Bank N A NY

NBT Bank N A NY grew its holdings in CVS Health Co. (NYSE:CVS – Get Rating) by 1.1% during the 4th quarter, Holdings Channel reports. The firm owned 53,115 shares of the pharmacy operator’s stock after buying an additional 587 shares during the period. NBT Bank N A NY’s holdings in CVS Health were worth $4,950,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of CVS. Davis Selected Advisers lifted its stake in shares of CVS Health by 0.3% during the fourth quarter. Davis Selected Advisers now owns 208,090 shares of the pharmacy operator’s stock valued at $19,392,000 after buying an additional 722 shares during the period. First Western Trust Bank lifted its stake in shares of CVS Health by 15.7% during the fourth quarter. First Western Trust Bank now owns 3,567 shares of the pharmacy operator’s stock valued at $332,000 after buying an additional 483 shares during the period. Thompson Siegel & Walmsley LLC lifted its stake in shares of CVS Health by 12.7% during the fourth quarter. Thompson Siegel & Walmsley LLC now owns 215,641 shares of the pharmacy operator’s stock valued at $20,096,000 after buying an additional 24,222 shares during the period. Simplify Asset Management Inc. raised its stake in CVS Health by 8.8% during the fourth quarter. Simplify Asset Management Inc. now owns 9,042 shares of the pharmacy operator’s stock worth $843,000 after purchasing an additional 728 shares during the period. Finally, Creative Planning raised its stake in CVS Health by 5.6% during the fourth quarter. Creative Planning now owns 180,102 shares of the pharmacy operator’s stock worth $16,784,000 after purchasing an additional 9,616 shares during the period. 77.29% of the stock is currently owned by institutional investors and hedge funds.

CVS Health Price Performance

Shares of CVS stock traded up $0.02 during midday trading on Friday, reaching $67.69. 4,165,511 shares of the company were exchanged, compared to its average volume of 8,918,504. CVS Health Co. has a 12 month low of $66.61 and a 12 month high of $107.26. The company has a market cap of $86.78 billion, a P/E ratio of 22.44, a PEG ratio of 1.25 and a beta of 0.61. The company’s 50 day moving average price is $72.74 and its two-hundred day moving average price is $84.92. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.67 and a current ratio of 0.92.

CVS Health (NYSE:CVS – Get Rating) last released its earnings results on Wednesday, May 3rd. The pharmacy operator reported $2.20 EPS for the quarter, beating the consensus estimate of $2.07 by $0.13. CVS Health had a net margin of 1.20% and a return on equity of 15.75%. The business had revenue of $85.28 billion during the quarter, compared to analyst estimates of $80.67 billion. During the same period in the prior year, the business earned $2.22 earnings per share. The business’s quarterly revenue was up 11.0% on a year-over-year basis. On average, sell-side analysts expect that CVS Health Co. will post 8.63 earnings per share for the current year.

CVS Health Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, May 1st. Stockholders of record on Friday, April 21st were issued a dividend of $0.605 per share. The ex-dividend date of this dividend was Thursday, April 20th. This represents a $2.42 dividend on an annualized basis and a dividend yield of 3.58%. CVS Health’s dividend payout ratio is currently 79.87%.

Wall Street Analyst Weigh In

A number of research firms have weighed in on CVS. TheStreet downgraded shares of CVS Health from a “b” rating to a “c” rating in a research note on Wednesday, May 3rd. Barclays cut their target price on shares of CVS Health from $100.00 to $90.00 in a research note on Thursday, May 4th. Bank of America cut their target price on shares of CVS Health from $111.00 to $104.00 and set a “buy” rating on the stock in a research note on Friday, March 31st. Truist Financial lowered their price target on shares of CVS Health from $115.00 to $109.00 in a report on Thursday, May 4th. Finally, Credit Suisse Group lowered their price target on shares of CVS Health from $125.00 to $96.00 in a report on Monday, May 8th. Three research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $108.75.

Insider Buying and Selling at CVS Health

In related news, CEO Karen S. Lynch acquired 14,000 shares of the company’s stock in a transaction on Wednesday, May 3rd. The shares were purchased at an average price of $69.75 per share, for a total transaction of $976,500.00. Following the purchase, the chief executive officer now owns 431,392 shares in the company, valued at $30,089,592. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 0.25% of the company’s stock.

About CVS Health

(Get Rating)

CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Pharmacy Services, Retail or Long-Term Care, Health Care Benefits, and Corporate and Other. The Pharmacy Services segment focuses on the pharmacy benefit management solutions.